DDInter119 DDInter1214
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Midostaurin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Midostaurin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Midostaurin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saxagliptin
Midostaurin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Midostaurin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Midostaurin {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midostaurin may lead to a major life threatening interaction when taken with Leflunomide
Midostaurin may lead to a major life threatening interaction when taken with Crizotinib